Related Experiment Video
Updated: May 15, 2025

Human Liver Microphysiological System for Assessing Drug-Induced Liver Toxicity In Vitro
Published on: January 31, 2022
Tirzepatide-Induced Liver Injury: A Rare Medication Side Effect
Meagan Phox1, John Thesing1, W Ransom Kilgore1
1Department of Internal Medicine, University of Kansas School of Medicine - Wichita, Wichita, KS.
Abstract:
Tirzepatide, an injectable agonist of glucagon-like peptide 1 and glucose-dependent insulinotropic polypeptide receptors, is used to treat type 2 diabetes mellitus and obesity. To our knowledge, there have been few reported cases of drug-induced liver injury (DILI) secondary to tirzepatide use. We report the experience of a 76-year-old woman who developed acute hepatitis following 8 weeks of tirzepatide use and a sixteen-pound weight loss. She was found to have elevated liver enzymes, and liver biopsy confirmed DILI. Though the mechanism underlying this DILI remains unknown, physicians should be aware of this rare side effect.
Related Concept Videos
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Antiepileptic Drugs: Potassium Channel Activators
Ezogabine has gained approval as an adjunctive treatment...
Dipeptidyl Peptidase 4 Inhibitors
Tissue-Drug Binding: Localization of Drugs and its Significance
Drugs can bind to different tissue components, enhancing their distribution and localization. The factors influencing drug localization in tissues include the drug's lipophilicity, structural characteristics, tissue perfusion rate, and pH differences. These factors determine...
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Skeletal Muscle Relaxants: Adverse Effects
Unlike...

